B. Patel

发表

Antisense Inhibition of Survivin Expression as a Cancer Therapeutic

P. Iversen, G. Sandusky, N. Stamm, 2011, Molecular Cancer Therapeutics.

γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.

B. Wood, S. Riddell, A. Salter, 2019, Blood.

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

D. Timm, R. Walgren, P. Ebert, 2018, Oncotarget.

Abstract 2819: Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling

P. Hipskind, Hong Gao, K. Credille, 2011 .

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Shobha N. Bhattachar, R. Campbell, Y. Qian, 2019, Molecular Cancer Therapeutics.

Biomarkers of the Hedgehog/Smoothened pathway in healthy volunteers.

S. Stepaniants, L. Brail, J. Brandt, 2012, American journal of translational research.

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

J. Soria, C. Massard, D. Sarker, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeting Apoptosis Pathways for Cancer Therapy

B. Patel, Bharvin Patel, 2005 .

Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer*

K. Pradhan, A. Hakimi, J. Greally, 2016, The Journal of Biological Chemistry.

A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.

Suzanne F. Jones, J. Bendell, H. Burris, 2016, European journal of cancer.

First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer.

J. Soria, C. Massard, C. Tourneau, 2015 .

Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.

P. Hipskind, Hong Gao, J. Manro, 2013 .